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ABSTRACT 
Phosphoinositide-3-kinase (PI3K) plays a key role in cellular metabolism and cancer. 
Using a mass spectrometry-based metabolomics platform, we discovered that 
plasma concentrations of 26 metabolites, including amino acids, acylcarnitines and 
phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors 
compared with non-tumor bearing controls and in addition were increased following 
dosing with Class I PI3K inhibitor pictilisib (GDC-0941). These candidate 
metabolomics biomarkers were evaluated in a Phase I dose-escalation clinical trial of 
pictilisib. Time- and dose-dependent effects were observed in patients for 22 plasma 
metabolites. The changes exceeded baseline variability, resolved after drug washout 
and were recapitulated on continuous dosing. Our study provides a link between 
modulation of the PI3K pathway and changes in the plasma metabolome and 
demonstrates that plasma metabolomics is a feasible and promising strategy for 
biomarker evaluation. Also, our findings provide additional support for an association 
between insulin resistance, branched-chain amino acids and related metabolites 
following PI3K inhibition. 
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INTRODUCTION 
The successful incorporation into the Pharmacologic Audit Trail of pharmacodynamic 
biomarkers can significantly increase the scientific rigor, decision-making reliability and 
hypothesis-testing power in drug development, and in particular help mitigate the risk of 
attrition by confirming target engagement and informing key decisions regarding optimal dose 
and schedule (1). In preclinical studies in oncology, solid tumor samples can readily be 
obtained from mice bearing human tumor xenografts to evaluate the effects of drugs. In the 
clinical situation where few patients have accessible tumor, this is challenging with pre- and 
post-treatment biopsies typically obtained in the best case scenarios (2). Consequently, 
biomarkers are often derived from surrogate tissues, for example platelet-rich plasma or 
blood mononuclear cells, which can be obtained in a minimally invasive way (3, 4).  In 
patients with metastatic disease, circulating tumor cells may be obtained but they are few and 
not systematically amenable to studies evaluating target engagement (5). Imaging 
technologies are very appealing and non-invasive but remain expensive and difficult to 
deploy across multiple centres (6).  
 
We hypothesised that circulating metabolites may present an attractive strategy to assess 
biomarker modulation in early phases of clinical drug development.  As a minimally invasive 
assessment, plasma metabolomic analysis has the potential to complement direct tumoral 
measurements and, particularly where cancer biopsies are unavailable, can report on the 
integrated output of multiple systems including sites of disease. There is no doubt that the 
signatures will include output from both normal tissues and cancers. However, given the 
increasing recognition that there is in fact a key bi-directional interplay between the two, this 
could be considered an advantage. Moreover, we reasoned that the PI3K axis (which is a key 
mediator of cellular metabolism) represents a desirable test system to evaluate this approach 
(7). It is thought to function as a critical logic gate with a nutrient-sensing role and controls the 
rate of metabolic processes including fatty acid synthesis, β-oxidation, oxidative 
phosphorylation and glycolysis (8, 9). This pathway is significantly associated with disordered 
metabolism, including insulin resistance, and is modulated by anti-diabetic interventions (10, 
11). The presence of germline PTEN mutations has been linked with constitutively increased 
insulin sensitivity and glucose tolerance in mice and humans (12, 13). There are thus strong 
a priori rationales for the study of the PI3K pathway to evaluate the potential of plasma 
metabolomics as a marker of target engagement in clinical studies. Multiple agents are in 
development that target key mediators of the PI3K pathway; among them, pictilisib (GDC-
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0941, Genentech Inc., South San Francisco, CL) is a potent and selective pan-Class I 
inhibitor of PI3K that is currently being assessed in randomized Phase II clinical trials (14-20).  
 
Using liquid chromatography mass spectrometry (LC-MS), we implemented a non-targeted 
exploratory screen for plasma metabolites exhibiting consistent changes across genetic and 
pharmacologic perturbations of the PI3K pathway in mouse models. We next evaluated the 
identified biomarker candidates in a dose-escalation clinical trial of pictilisib, seeking dose- 
and time-dependent changes in patients with advanced cancers following drug 
administration. The confirmation of plasma metabolite changes in patients undergoing 
pharmacological inhibition of PI3K demonstrates the feasibility and promise of this approach 
for minimally invasive biomarker development. The metabolite changes we observed are 
consistent with the development of an insulin resistance phenotype following treatment with a 
pan-Class I PI3K inhibitor. 
 
on May 8, 2016. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2016; DOI: 10.1158/1535-7163.MCT-15-0815 
Ang et al; Plasma metabolome changes in response to PI3K inhibition 
 
 
6 
 
MATERIALS & METHODS 
The experimental workflow is presented in Fig. 1A. In the exploratory preclinical 
screening studies, we compared plasma from: (1) tumor-bearing PTEN (+/-) C57BL/6 
euthymic mice with non-tumor-bearing wild-type littermate controls; and (2) athymic 
mice inoculated subcutaneously with or without PTEN (-/-) U87MG glioblastoma or PC3 
prostate human tumor xenografts (21). Some of the mice were treated with pictilisib 
(100 mg/kg) or vehicle controls at 2, 4, 8 and 24 hours post-dosing. We compared the 
effects in plasma and tumor of another chemically distinct oral pan-Class I PI3K inhibitor 
(buparlisib) with those for pictilicib at 8 hours following a single dose. We also 
determined plasma metabolite profiles of athymic mice bearing U87MG tumor 
xenografts dosed with vehicle or a representative cytotoxic agent (carmustine; BCNU).   
 
At the subsequent clinical evaluation stage, within the framework of a Phase I dose-
escalation trial, we first monitored the levels of the candidate plasma metabolite 
biomarkers on two separate days within a 2-week screening window, prior to treatment, 
in order to define baseline levels. This was followed by determining the plasma 
metabolite changes, relative to pre-treatment baseline, at 2, 8 and 24 hours post-
treatment with different dose levels of pictilisib following oral administration of an initial 
single dose on day 1. A longitudinal study was then carried out following continuous 
once-daily oral dosing of pictilisib from day 8 in patients treated at the maximally 
tolerated dose (or higher) of pictilisib. Plasma metabolites were assessed pre-dose and 
at 1 hour post-dose on day 8 and pre-dose and at 2, 8 and 24 hours on day 15. 
 
Preclinical mouse models 
All animal experiments were conducted in accordance with local and United Kingdom 
National Cancer Research Institute guidelines (22). Female mice with heterozygous (+/-
) PTEN knockout (23) (n=5) on the C57BL/6 background and 25 week old age-matched 
wild-type littermates (n=6) were bled synchronously in the same experiment. To 
generate the tumor xenograft-bearing models, 2 million human cancer cells were 
injected subcutaneously bilaterally into the flanks of NCr athymic mice of 6 to 8-weeks 
of age, bred in-house; PC3 human prostate cancer cells and U87MG human 
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glioblastoma cells were administered into male and female mice respectively. Cell lines 
were obtained from ATCC in 2006 and used within 6 months of purchase. 
Authentication of the cell lines was subsequently performed in-house Cell lines were 
analyzed by short tandem repeat (STR) profiling. Polymorphic STR loci were amplified 
using a polymerase chain reaction (PCR) primer set. The PCR product (each locus 
being labelled with a different fluorophore) was analyzed simultaneously with size 
standards using automated fluorescent detection. The number of repeats at 7-10 
different loci was used to define the STR profile and this was cross-referenced with 
online databases to confirm authenticity. 
 
During the course of the experiment, food pellets (Certified Rodent Diet 5002, Labdiet, 
Indianapolis, Indiana, USA) and water were available ad libitum. Dosing of each drug 
and its respective vehicle control was undertaken synchronously in the same 
experiment when tumors were well-established and measured approximately 8-10 mm 
in diameter. Carmustine was prepared in 5% ethanol and 0.5% sterile saline, pictilisib or 
buparlisib in 10% DMSO, 5% Tween 20 and 85% sterile saline. Compounds were 
dosed in 0.1 mL/10 g body weight of vehicle once or twice daily (carmustine intra-
peritoneally at 20 mg/kg; pictilisib by oral gavage at 50 or 100 mg/kg; buparlisib by oral 
gavage at 60mg/kg); these represented biologically active, well tolerated doses 
associated with modulation of known downstream pharmacodynamic biomarkers of 
PI3K inhibitors (17). Control animals received an equivalent volume of appropriate 
vehicle. Blood samples were collected into bottles using sodium heparin as 
anticoagulant at 2, 8 and 24 hours post-drug administration. The samples were 
centrifuged at 13000 rpm for 2 minutes and then transferred onto dry ice; the entire 
process from collection to storage in dry ice took less than 5 minutes per sample. Three 
to six mice were used for each time point per treatment. Following completion of the 
entire experiment, the samples were stored at -80oC until further analyses. 
 
Phase I dose-escalation clinical trial of pictilisib 
Plasma samples for metabolomic analysis were obtained from 41 patients with 
advanced cancers treated at The Royal Marsden NHS Foundation Trust, London, 
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United Kingdom, in a Phase I study of pictilisib with a standard 3+3 dose-escalation 
design (24). Pictilisib was administered orally on day 1, followed by a one-week 
washout, and dosing was once-daily on either a 21- or 28-day dose schedule every 28 
days. The assessed dose levels ranged from 45 mg to 450 mg (45 mg [n=2], 60 mg 
[n=4], 80 mg [n=3], 100 mg [n=4], 245 mg [n=1], 330 mg [n=16], 340 mg [n=7], 400 mg 
[n=1], 450 mg [n=3]). In this study, the maximal tolerated dose was 330 mg 
administered once daily (20). Of 35 patients with RECIST-measurable disease in whom 
metabolomic analysis was undertaken, one achieved a partial response, 28 achieved 
stable disease and 6 sustained progressive disease (20). Study duration in this cohort 
of patients ranged from 7 to 288 days. Notably, there was marked heterogeneity in the 
primary tumor type. For all dose levels assessed in this study, metabolomic samples 
were collected pre-dose and 2, 8 and 24 hours post-dose on day 1. In 17 patients 
treated with pictilisib at dose levels ≥330 mg, once daily, samples were collected at the 
following additional time points following a protocol amendment: baseline at screening 
within 2 weeks prior to day 1, pre-dose and 1 h post-dose on day 8; and pre-dose and 
2, 8 and 24 hours post-dose on day 15. All patients were fasted for at least 2 hours prior 
to each sampled time point but were permitted water ad libitum. Plasma was separated 
from blood (using sodium heparin as anticoagulant) following centrifugation at 1500 g 
for 15 minutes at 4oC; it was then stored at -80oC until further analyses. The schedule of 
sample collection is presented in Fig. 1B. Non-mandated immunohistochemical analysis 
including phospho-AKT (Ser473) of tumor biopsies was undertaken but these were 
limited in number and graded on a semi-quantitative scale. The 
electrochemiluminescense-based assay of phospho-AKT (Luminex xMAP; Luminex 
Corp.) of surrogate platelet-rich plasma was only conducted late in the trial at the dose 
expansion phase. These limited our ability to perform exploratory assessments of their 
relationship with the observed metabolomic changes and additionally highlight 
challenges in performing pharmacodynamic assessments in Phase I trials. At dose 
levels ≥100 mg, plasma was obtained pre-dose and at 1 hour after dose on cycle 1 day 
1 for analysis of glucose and insulin levels. Estimates of insulin resistance were derived 
based on the Homeostasis Model Assessment model (25). Non-mandated whole-body 
18FDG-PET scans were performed at baseline, and 1 to 4 hours after dose between day 
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22 and the end of cycle 1. In all, 23 and 13 respective patients who underwent 
metabolomic analysis also undertook glucose/insulin and 18FDG-PET studies. All 
aspects of the study were conducted in accordance with the Declaration of Helsinki and 
the International Conference on Harmonization Good Clinical Practice Guidelines. 
Written informed consent was obtained from all participants. 
 
Plasma metabolomics analysis 
Non-targeted LC-MS metabolomics was initially used in the preclinical screen as 
described previously (26); significant changes in plasma metabolites were identified. To 
follow up and confirm these preliminary findings, we carried out targeted, quantitative 
metabololomic analysis by electrospray ionization tandem MS using the AbsoluteIDQTM 
p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria); results from the confirmatory, 
quantitative platform are presented in this report. Samples were anonymized and 
analyses were carried out on a Waters Acquity H-class UPLC coupled to Xevo TQ-S 
triple-quadrupole MS/MS System (Waters Corporation, Manchester, UK). Quantification 
of the metabolites of the biological sample was achieved by reference to appropriate 
internal standards. The method conforms with the United States Food and Drug 
Administration Guidelines ‘Guidance for Industry – Bioanalytical Method Validation (May 
2001)’, providing proof of reproducibility within a given error range.  
 
Data analysis 
The analytical process to derive metabolite concentrations was performed using the 
MetIDQ software package. The data matrix obtained was subsequently subjected to 
multivariate analysis using SIMCA v.13 software (MKS Umetrics AB, Sweden); 
metabolite features that were differentially expressed between defined groups of mice: 
(1) PTEN (+/-) mice versus wild type littermates; (2) PC3-bearing versus non-tumor-
bearing mice; (3) U87MG-bearing versus non-tumor-bearing mice; and (4) pictilisib-
treated (100 mg/kg) versus vehicle control-treated mice bearing PC3 prostate tumors or 
U87MG glioblastoma). Metabolites responsible for changes were identified using 
orthogonal partial least square-discriminant analysis (OPLS-DA) (27) with a threshold of 
variable importance in the projection (VIP) value >0.8. To pass the exploratory 
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preclinical screen, a metabolite was required to change consistently across both 
xenograft-bearing mouse models treated with pictilisib (passing the OPLS-DA filter) and 
at least one other preclinical model involving the transgenic PTEN (+/-) or PTEN null 
tumor xenograft-bearing mice (compared with wild-type and non-tumor-bearing 
littermates, respectively) with no contradictory change in any other model. Permutation 
analysis was carried out for model validation. Heat maps were generated using the 
concentration changes relative to vehicle control animals at each time point. In the 
clinical study, changes relative to pre-treatment baseline levels on day 1 were 
calculated for each patient across all time points; the geometric mean, associated 95% 
confidence intervals and p-values (H0: no different between pre- and post-treatment 
levels) of relative change were estimated for each time point and dose range (low: 45-
60 mg [n=6]; mid: 80-245 mg [n=8]; high: 330-450 mg [n=27]). For unsupervised 
multivariate analysis, principal component analysis (PCA) was undertaken using SIMCA 
v.13 software. In addition, the SPSS program (v.21, Chicago, USA) and GraphPad 
Prism (v.6, California, USA) were used for all other statistical analyses. All p-values 
presented are two-sided and values <0.05 were considered statistically significant.  
 
RESULTS 
Preclinical models 
Mice with PTEN-deficient tumors have distinct plasma metabolite profiles 
At 8 weeks of age, no significant differences were observed in the plasma metabolite 
profile between genetically engineered PTEN (+/-) mice with no observable 
macroscopic tumors compared with wild-type littermates. At 25 weeks, palpable tumors, 
splenomegaly and thymic enlargements were observed in the PTEN (+/-) mice. Using 
OPLS-DA, the concentrations of 53 plasma metabolites were found to be significantly 
decreased in PTEN (+/-) transgenic mice compared with wild-type littermates.  
 
In addition, when mice harboring human tumor xenografts were compared with non-
tumor bearing littermates, a decrease was observed in the levels of 60 and 17 plasma 
metabolites for the PTEN-negative PC3 prostate and U87MG glioblastoma models 
respectively. The overlap of the changes seen in the human tumor xenografts and the 
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PTEN-depleted transgenic mouse tumors is illustrated in Fig. 2A. Twelve plasma 
metabolites were consistently altered across all three animal models, with reductions 
seen in the PI3K pathway-aberrant tumor-bearing mice; metabolites affected included 
amino acids, acylcarnitines and phospholipids. We note that the greatest overlap was 
between the PTEN-depleted versus wild-type littermates and the PC3 tumor-bearing 
versus non-tumor-bearing comparison. Regardless of the number of plasma metabolites 
identified in each comparison, the majority of changes in each case were common to 
the three models. Of note, high degrees of separation between the experimental (tumor-
bearing, transgenic or treated animals) and the relevant control groups were observed 
in the OPLS-DA, with all R2>0.8 and Q2>0.6 (representing the explained variance and 
predictive capability in the internal cross-validation, respectively).  
 
In contrast to the number of metabolites noted above showing decreased plasma levels, 
only a few metabolites across the panel assessed were elevated in the xenograft tumor-
bearing mice and none was significantly elevated in the PTEN-depleted model. 
 
Potent and specific pharmacological inhibition of Class I PI3K using pictilisib is 
associated with changes in the plasma metabolome 
We sought to examine the circulating metabolite changes at doses of pictilisib inhibiting 
the phosphorylation of AKT Ser473 over 24 hours in platelet rich plasma (17). OPLS-DA 
of the comparisons between plasma metabolites in pictilisib (at 100 mg/kg) and control 
vehicle-treated mice revealed an increase in the concentrations of 49 and 32 plasma 
metabolites in mice bearing PC3 and U8MG tumors respectively. Of these, 28 
metabolites were common to both models (Fig. 2B). Moreover, these metabolites were 
similarly increased in mice bearing U87MG human tumor xenografts treated with 100 
mg/kg GDC-0941 or 60 mg/kg buparlisib (Supplementary Fig. 1). When these pictilisib 
treatment-related changes were compared with those illustrated in Fig. 2A, 10 plasma 
metabolites were observed to exhibit variations consistent across all 5 models: 13 
metabolites in 4 of 5 models and 3 metabolites in 3 of 5 models.  
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Based on these data, a panel of 26 plasma metabolites was selected for further clinical 
evaluation. The relevant changes observed in this panel of 26 metabolites across the 
various models along with their patterns of overlap are summarized in Fig. 2 and 
Supplementary Table 1. 
 
The plasma concentrations of 6 of 9 essential amino acids (histidine, phenylalanine, 
threonine, valine. isoleucine and tryptophan) were significantly decreased in the 
genetically engineered PTEN+/- tumor-bearing animals and subsequently increased 
following treatment with pictilisib in these mice. The levels of non-essential amino acids, 
including asparagine, citrulline, glutamate and serine, were similarly decreased in the 
tumor-bearing animals and increased following treatment with pictilisib in tumor-bearing 
mice. The concentrations of acylcarnitines (with the following acyl-side chains: C3, C5, 
C16, C14:2-OH, C16:1-OH, C18, C18:1 and C18:1-OH) were lower in the plasma of 
PTEN (+/-) animals and/or PC3-bearing mice compared with control animals and in 
addition were increased following pictilisib administration in both PC3- and U87MG 
tumor-bearing mice. Significant changes in phosphocholine metabolism were observed 
with lysophosphatidylcholine C18:1, C20:3 and C20:4, acyl-acyl phosphatidylcholine 
C36:0, and acyl-alkyl phosphatidylcholines C40:1, C42:3 and C42:4 decreased in at 
least one tumor-bearing model and increased following pictilisib treatment of tumor-
bearing mice.  
 
Thus, following the administration of a single dose of pictilisib at doses where AKT 
phosphorylation is inhibited (17), the observed increase in the plasma concentrations of 
the candidate biomarkers in both tumor-bearing models represented a reversal of 
changes observed in the presence of PTEN-deficient tumors (Fig. 3). The post-
treatment changes were generally greater in the PC3-bearing mice, occurred mainly 
after 4 hours, and persisted for up to 24 hours or more post-dose (Fig. 3). The 
metabolite changes observed in plasma from U87MG-bearing mice following treatment 
with pictilisib were mirrored following treatment with buparlisib (Supplementary Fig. 1).  
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In contrast to pictilisib treatment of tumor-bearing mice, there was a general trend of 
reduction, rather than an increase, of the metabolites following administration of the 
PI3K inhibitor to non-tumor-bearing mice. Of note, a transient and slight increase in 
plasma levels of amino acids was followed by a reduction in their levels from 4 to 6 h 
post-dose.  
 
The metabolite changes described above are represented in the heat map in Fig. 3A. 
Taken together, the data define a set of changes in the plasma metabolome that are 
responsive to genetic and pharmacologic perturbation of the PI3K pathway.  
 
The chemotherapeutic agent carmustine induces plasma metabolite changes distinct 
from those following PI3K inhibition in U87MG tumor-bearing mice 
As an additional control, we additionally investigated changes in the plasma metabolites 
described above in U87MG tumor-bearing mice following treatment with carmustine as 
a chemotherapeutic clinical standard of care for glioblastoma. The observed changes 
were different from those in pictilisib-treated tumor-bearing mice. In the carmustine-
treated U87MG-bearing mice, 2 distinct groups of plasma metabolite changes were 
observed: (1) the amino acids and short chain acylcarnitines showed a reduction in level 
followed by an increase at 8 hours post-dose; and (2) the long chain acylcarnitines and 
phosphatidylcholines generally increased acutely and then decreased from 4 hours 
post-dose (Fig. 3A).  
 
The major differences in plasma metabolome changes for the cytotoxic agent 
carmustine versus the selective PI3K inhibitor pictilisib provide evidence in support of 
specificity for the effects seen with the latter agent. 
 
Baseline characteristics of participants in Phase I dose-escalation clinical trial of 
pictilisib 
Plasma samples were obtained from 41 advanced cancer patients with no conventional 
treatment options who participated in a dose-escalation clinical trial of pictilisib (20, 24). 
The treatment dosing and plasma sampling schedules are summarized in Fig. 1B. 
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Modulation of mechanism-based pharmacodynamic biomarkers, including 
phosphorylation of S6 ribosomal protein and AKT as well as 18FDG-PET uptake, was 
observed at dose levels ≥80 mg once-daily (20, 24).  
 
Clinical evaluation of candidate plasma metabolite biomarkers 
For the 26 plasma metabolome biomarkers selected from the non-targeted exploratory 
preclinical study described above, the mean intra-patient coefficient of variation in 
baseline clinical plasma samples ranged from 7 to 47%. Apart from C14:2-OH 
acylcarnitine and acyl-acyl phosphatidylcholine C36:0, all metabolites had a mean 
coefficient of variation of <20% (Supplementary Table 2). Further clinical evaluation was 
not carried out for the 2 metabolites with high coefficients of variation, leaving 24 
metabolites that we pursued further. 
 
Following single dose pictilisib treatment on day 1, dose- and time-dependent changes 
were observed in 22 of these 24 candidate biomarkers, with only C18 acylcarnitine and 
acyl-alkyl phosphatidylcholine C42:4 not changing significantly (Fig. 3B). The maximal 
changes post-treatment were greater than baseline variability for each of these 
metabolites (Supplementary Tables 2, 3 and 4). Significant changes were observed 2 
hours post-dose in 13 of 24 metabolites and were detected only at doses of pictilisib 
≥80 mg. This modulation of circulating biomarker coincides with doses where inhibition 
of AKT phosphorylation Ser473 was observed in platelet rich plasma (20). The highest 
number and the most significant changes occurred at 8 hours post-dose with 19 of 24 
candidate metabolites showing statistically significant changes; persistence of these 
changes was seen at 24 hours post-dose for 18 metabolites. Only 3 metabolites 
demonstrated significant changes following administration of pictilisib in the lowest dose 
range (<80 mg once-daily); these changes were observed at 8 hours post-dose only. At 
8 and 24 hours post-administration, the greatest frequency of statistically significant 
changes was associated with the highest dose range. The observed changes were 
generally consistent with that seen in the pictilisib-treated tumor-bearing mice, the only 
exception being the long chain acylcarnitines for which a decrease was observed in 
patients following pictilisib treatment. The latter changes were more similar to those 
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seen in the non-tumor bearing as opposed to the tumor xenograft-bearing mice. The 
various changes are summarized in Figs. 3B and 4 and presented in Supplementary 
Table 3. The levels of each metabolite relative to time 0 for each patient is presented in 
supplemental Table 5.  
 
In 17 patients treated with pictilisib at doses ≥330 mg once-daily, additional plasma 
samples were obtained on days 8 and 15 of the continuous dosing phase. Note that all 
patients received a single dose of pictilisib on day 1, followed by a one-week drug 
holiday; dosing recommenced on day 8 on a continuous once-daily schedule. 
Importantly, following dosing on day 15, the trends and directionality of pictilisib-induced 
metabolome changes for the panel of 24 candidate metabolite biomarkers were similar 
to those observed for day 1 dosing. To illustrate this, plots of selected metabolites and 
metabolite classes are presented in Fig. 5 and detailed results of these analyses are 
provided in Supplementary Table 2.  
 
Of the panel of 24 metabolites, none exhibited a significant change from the original 
baseline concentration prior to recommencement of pictilisib on day 8, indicating a 
return to baseline after drug washout. Just prior to dosing on day 15, only 4 metabolites 
were significantly different from baseline levels. 
 
We conclude that for the Phase I cohort of patients studied, we demonstrated 
successful translation and validation of the targeted panel of plasma metabolites 
responsive to PI3K inhibition that we initially discovered in the preclinical non-targeted 
exploratory screen. 
 
Exploratory assessment of relationship between metabolite changes with other 
pharmacodynamic and clinical parameters 
Unsupervised multivariate analysis based on the 22-metabolite signature revealed an 
association between higher dose levels, longer study durations, greater insulin 
resistance with increase in amino acid and short chain acylcarnitine levels but decrease 
in SUVmax and levels of long chain acylcarnitines (Fig. 6). 
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DISCUSSION  
In this study, we show that a panel of circulating metabolite biomarkers we discovered 
for assessing target engagement in experimental models have successfully translated 
to a Phase I clinical trial. Perturbations of the PI3K pathway induced either by genetic or 
pharmacological means resulted in changes in the plasma metabolome, comprising 
amino acids, acylcarnitines and phosphatidylcholines. We show that the concentrations 
of 26 plasma metabolites were decreased in various mouse models of PTEN-deficient 
tumors and increased following treatment with pictilisib (a potent and specific pan-class 
I inhibitor of PI3K) in mice bearing PTEN-deficient human prostate and glioblastoma 
tumor xenografts. Excluding the 2 plasma metabolites with high physiological baseline 
variability, we found that 22 of 24 of the identified plasma metabolome biomarker 
candidates exhibited significant dose- and time-dependent changes in response to PI3K 
inhibition when evaluated in the dose-escalation Phase I clinical trial of pictilisib.   
 
Although an increasing number of novel inhibitors of the PI3K pathway are entering 
clinical trials, currently available pharmacodynamic biomarkers are restricted by issues 
including biomarker signal lability, risk of sampling complications, limited sensitivity and 
throughput, high costs of the associated analytical methods and lack of amenability to 
repeated sampling (2). In this context, the present study provides a general framework 
for the rational discovery of pharmacodynamic plasma metabolite biomarkers. In the 
preclinical exploratory stage, we generated a panel of PI3K-responsive metabolomics 
plasma biomarker candidates from model systems that are genetically defined and 
maintained under a well-controlled laboratory environment. These metabolite 
biomarkers were subsequently assessed and confirmed in the clinical stage where time- 
and dose-dependencies of the candidate metabolite biomarkers were carefully 
evaluated. The use of a combination of orthogonal genetic and pharmacologic 
preclinical pathway perturbation models to screen for mechanism-based metabolite 
candidates provided increased rigor, decreasing the likelihood of false positive leads, 
and also reduced the size of the panel of potential metabolite biomarkers for 
subsequent targeted analysis. In addition, the chosen LC-MS analytical platform is 
robust, reproducible and high throughput; sample preparation for a 96-well plate takes 
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about 2 hours and MS data acquisition is completed after 12 hours. This is on a 
background of generally increasing affordability and uptake of LC-MS instrumentation in 
recent years. 
 
Importantly, the changes observed in the majority of metabolites that we discovered in 
the preclinical screen were subsequently confirmed in a Phase I clinical trial setting, 
providing confidence in the preclinical biomarker discovery strategy. Since an 
analytically validated, quantitative platform was used to generate absolute 
concentrations of the assessed metabolites, we were therefore able to compare the 
data obtained in preclinical models and those in patients. 
 
We and others have previously shown that the interpretation of clinical metabolite 
pharmacodynamic data is challenging and may be confounded by variables such as 
food and diurnal variation (28-30). To circumvent these potential effects, we carried out 
multiple clinical measurements including: (1) assessment of baseline pre-treatment 
variability in metabolites of interest taken on two separate days; (2) examination of the 
relationship between metabolite changes and dose levels on day 1 of the clinical trial; 
and (3) comparison of metabolite concentrations in patients treated at the maximal 
tolerated dose or higher. In addition, plasma levels over 24h on day 15 following a week 
of continuous once-daily oral dosing were compared with concentrations on day 8 after 
1 week washout after drug administration. In our clinical study of 41 patients, the 
majority (22 of 24) of our identified biomarker candidates demonstrated consistent 
changes across these assessments and the observed changes post-treatment were 
significantly greater than pre-treatment baseline variability (Supplementary Tables 2, 3 
and 4). These effects occurred at pictilisib doses for which mechanism-based biomarker 
modulation (plasma glucose and insulin levels, phosphorylated S6 ribosomal protein 
and AKT as well as 18FDG-PET uptake) has already been observed in the clinical study 
(20). The concordance of these clinical observations with our preclinical findings 
increases the likelihood that the plasma metabolite changes that we observed are 
genuinely associated with systemic PI3K pathway modulation. Furthermore, an 
exploratory unsupervised multivariate analysis including patients in whom mechanism-
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based pharmacodynamics was concurrently performed revealed associations between 
insulin resistance, 18FDG-PET changes and candidate plasma metabolites. Importantly, 
these observations increased our confidence of the choice of the recommended Phase 
II dose-schedule.  
 
The present study has provided proof-of-feasibility for the use of a broad, systems-
based strategy, translating from mouse models to a Phase I clinical trial setting, to 
identify effects on the metabolome. We identified numerous amino acids in the plasma, 
including the branched chain (BCAA) and aromatic (AAA) amino acids, along with the 
products of their catabolism, the short-chain C3 and C5 acylcarnitines that were down-
regulated in the presence of PTEN-depleted tumors. Moreover, we showed that these 
changes were reversed by PI3K pathway inhibition using the pan-class I PI3K inhibitor 
pictilisib. Importantly, elevated levels of these plasma metabolites have been 
consistently associated with insulin resistance, are predictive of the risk of developing 
diabetes mellitus, and are highly responsive to anti-diabetic interventions (31-35). 
Furthermore, numerous studies have demonstrated a direct role of BCAA and AAA in 
contributing to the development of insulin resistance. The infusion of amino acids 
(particularly BCAA) into humans and animals has been shown to lead to insulin 
resistance, accompanied by activation of mTOR, S6K1 and phosphorylation of IRS-1 
(36). Addition of BCAA or AAA to cultured muscle cells in vitro leads to activation of 
mTOR and impairment of insulin-stimulated phosphorylated AKT and glucose uptake 
(37). Amino acids such as leucine and glutamate are also potent insulin secretagogues 
(38). To put our metabolite findings into pharmacologic context, dose-dependent 
hyperglycemia and hyperinsulinemia were reported in the Phase I clinical trials of 
pictilisib and buparlisib (20, 24, 39). The adverse event of hyperglycemia was the dose-
limiting toxicity of the latter agent. The acute and chronic pharmacologic inhibition of the 
PI3K pathway has been shown to impact differentially on glucose homeostasis; 
specifically, chronic dosing of pan-class I inhibitors was associated with an attenuation 
of treatment-related hyperglycemia but not insulin sensitivity (40, 41). Furthermore, 
chronic genetic inhibition of p110α was found to protect mice from age-related reduction 
in insulin sensitivity, glucose tolerance and fat accumulation (42).  
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The increase in short chain acylcarnitines that we observed is consistent with the 
reported PI3K-AKT signaling and is linked to suppression of β-oxidation via inhibition of 
carnitine palmitoyltransferase 1a (CPT1a) gene expression and a glucose-addicted 
phenotype (8, 43). Based on this model, one would expect an increase in CPT1a level 
following pharmacologic PI3K inhibition and hence an increase in long chain 
acylcarnitine levels. We observed such changes consistently in both of the pictilisib-
treated human tumor xenograft mouse models studied here. This has also been 
reported by others in human cancer cells treated in vitro (43). However, contrary to 
expectations, a significant decrease in the plasma levels of these particular metabolites 
was observed in humans, an effect that is similar to the changes we observed in non-
tumor-bearing mice following pictilisib treatment. Lower levels of long chain 
acylcarnitines (in contrast to their C3 and C5 counterparts) have been linked to insulin 
resistance and may partly explain our findings (34). The regulation of plasma long chain 
acylcarnitine level is complex and reflects the balance between processes such as fatty 
acid synthesis and hydrolysis and β-oxidation. The described differences between 
murine and human mitochondrial β-oxidation of long chain fatty acids may also account 
for the differences that we observed (44).  
 
Our studies show a significant increase in specific lysophosphatidylcholines and 
phosphatidylcholine following treatment with pictilisib in plasma and tumor.  This is in 
contrast with observations in glioblastoma cells by NMR where decreases in total 
glycerophosphocholine and phosphocholine have been reported largely supported by 
by the decrease in choline kinase (45, 46). However, other studies performed by 31P-
NMR in breast cancer models have reported an increase in these metabolites attributed 
to increased levels of phospholipase A2 group 4A (47).  Lysophosphatidylcholine 
acyltransferase 1 (LPCAT1), has been studied in colorectal, gastric and prostate 
cancers (48-50) where low plasma levels of these metabolites are associated with the 
presence of cancer, supporting our preclinical findings. Lysophosphatidylcholines 
enhance glucose-dependent insulin secretion from pancreatic β-cells and inhibit insulin-
induced AKT activation through protein kinase C α in vascular smooth muscle cells (51, 
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52). Interestingly, the long chain carnitines, lysophosphatidylcholine and 
phosphatidylcholine that were significantly increased in our studies are even-chain. It 
has been shown that the associated even-chain saturated fatty acids are positively 
associated with diabetes mellitus whilst odd-chain derivatives are inversely associated 
with it (53).  
 
We observed that the plasma levels of the vast majority of our large panel of 
metabolites in the transgenic PTEN (+/-) mice were considerably lower compared with 
wild-type littermates. These changes showed a significant overlap with plasma 
metabolite levels we determined in the presence of PTEN null human tumor xenografts, 
especially the PC3 prostate carcinoma. Our results are consistent with published clinical 
data on plasma amino acids being reduced in a large series of patients with advanced 
cancer although they are contradicted by data from smaller studies (54, 55). We note 
also that the metabolite changes were greater in mice harbouring PC3 prostate 
carcinoma compared with U87MG glioblastoma xenografts; pictilisib is a P-glycoprotein 
substrate and the marked difference in P-glycoprotein expression between the two 
xenografts (absent in the former and present in the latter) may have contributed to this 
observation (56,57). 
 
Whilst the assessment of plasma metabolomics in patients cannot distinguish between 
tumor- and non-tumor-related changes, it is interesting that the plasma metabolite 
changes that we observed following pictilisib treatment between tumor- and non-tumor-
bearing animals were distinct. We propose that this difference may be attributed to the 
presence of tissue with a hyperactivated PI3K pathway in the former. PTEN null human 
tumor xenografts were chosen to increase the likelihood of detecting pathway-related 
metabolic changes, i.e. drug inhibition of a hyperactivated pathway. Further follow-up 
studies are now required to determine metabolome profiles in a wider range of tumor 
models with different PI3K pathway activation status and using various PI3K pathway 
inhibitory drugs and other molecular targeted inhibitors.  
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In summary, using an analytically validated, highly sensitive, high-throughput, LC-MS-
based metabolomics approach, we have identified distinct plasma metabolome changes 
that were consistently altered across different preclinical tumor models in which the 
PI3K pathway is activated by PTEN depletion. In the clinical evaluation of the candidate 
pharmacodynamic plasma metabolome biomarkers, time- and dose-dependent changes 
were observed for the majority of the metabolites. These findings suggest that under 
controlled conditions, plasma metabolomics is a valid tool to assess biomarker 
modulation in early clinical studies.  
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LEGENDS FOR TABLES AND FIGURES 
 
Figure 1: (A) Experimental workflow. (B) Schema illustrating once-daily dosing 
schedule of pictilisib (each green arrow representing a dose administered) with the 
plasma sampling schedule for metabolomic analysis summarized in the sub-table. 
 
Figure 2: Venn diagrams showing the overlap in plasma metabolites between 
preclinical animal models: (A) PTEN +/- (depleted) versus wild-type littermates and 
athymic mice bearing PTEN null human PC3 prostate carcinoma or U87MG 
glioblastoma xenografts compared with non-tumor bearing age-matched controls; 
(B) treatment with pictilisib versus vehicle in PC3- and U87MG-bearing mice; and (C) 
overlap between changes in all 3 models in (A) and those common to both models in 
(B). Metabolites that were further evaluated in the clinical setting are enclosed by a 
thick black line. (Tx: treatment) 
 
Figure 3: (A) Heat map of differences between transgenic PTEN-deficient tumor-
bearing mice compared with their normal PTEN wild-type  littermates (change 
relative to control) and changes across time in candidate plasma metabolite 
biomarkers following treatment with pictilisib or carmustine (relative to vehicle 
control) in tumor and non-tumor bearing mice.  (a, acyl; aa, acyl-acyl; ae, acyl-alkyl; 
Cx:y, where x is the number of carbons in the fatty acid side chain; y is the number 
of double bonds in the fatty acid side chain; AC, acylcarnitine; DC, decarboxyl; M, 
methyl; OH, hydroxyl; PC, phosphatidylcholine) (B) Heat map (in right panel with 
header labelled ‘HUMAN’) of statistically significant changes (relative to baseline) in 
plasma concentrations of metabolite biomarker candidates in patients treated in the 
dose-escalation trial of pictilisib. Juxtaposed (in left panel with header labelled 
‘MOUSE’) are changes seen in selected preclinical models as shown in Figure 3A. 
Highlighted in yellow are the dose levels of pictilisib at which modulation of 
mechanism-based pharmacodynamic biomarkers including phosphorylated S6 
ribosomal protein and AKT, and 18FDG-PET were observed. (a, acyl; aa, acyl-acyl; 
ae, acyl-alkyl; Cx:y, where x is the number of carbons in the fatty acid side chain; y is 
the number of double bonds in the fatty acid side chain; AC, acylcarnitine; DC, 
decarboxyl; M, methyl; OH, hydroxyl; PC, phosphatidylcholine) 
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Figure 4:  Percentage change relative to baseline of selected plasma metabolites at 
2, 8 and 24 hours post-pictilisib dosing in 41 patients treated at different dose levels. 
Geometric means with 95% confidence intervals are represented in the plots. 
(BCAA, Branched chain amino-acids; AAA, aromatic amino-acids; PC, 
phosphatidylcholine)  
 
Figure 5:  Percentage change relative to baseline of selected plasma metabolites at 
planned time points over 2 weeks on pictilisib treatment in 17 patients treated at 
dose levels ≥330 mg once-daily. Geometric means with 95% confidence intervals 
are represented in the plots. Other details are as indicated in the legend to Figure 4. 
 
Figure 6. PCA biplot comprising superimposed scatter and loading plots showing 
relationship between plasma metabolite changes (as X components), insulin 
resistance (IR), study duration and SUVmax (as Y components) as well as dose of 
pictilisib (labelled for each observation) (n=13 patients). Clustering of changes in 
levels of branched chain and aromatic amino acids, study duration and insulin 
resistance is noted; these variables are broadly related to inverse changes in SUVmax 
and changes in long chain acylcarnitines and lysophosphatidylcholine levels.  
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